Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending dose study of PG110 in knee osteoarthritis pain
NL-OMON35149Phase 1Active, not recruiting
- Sponsor
- Abbott Laboratories
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in knee osteoarthritis (OA) comparing PG110 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2009; status: active, not recruiting.
02
Drugs
Hu-alphaD11
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON35149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35149.